Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold 100,000 shares of common stock on May 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard Lowenthal, the President and CEO of ARS Pharmaceuticals, sold 100,000 shares of the company's common stock on May 7, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• 50,000 shares were sold at a weighted average price of $9.3427, with prices ranging from $9.14 to $9.50.
• Another 50,000 shares were sold at a weighted average price of $9.3446, also with prices ranging from $9.14 to $9.50.
• Following these transactions, Lowenthal directly owns 4,315,313 shares.
• Lowenthal also has indirect ownership through various trusts, including the Richard Lowenthal Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and shares held by his spouse and the Sarina Tanimoto Charitable Remainder UniTrust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Risks

• Sales by insiders, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates